Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 for Nasal Decolonisation of Staphylococcus Aureus
Status:
Completed
Trial end date:
2022-10-28
Target enrollment:
Participant gender:
Summary
A Phase IIa, double-blind, placebo-controlled, randomised study designed to evaluate the
efficacy, safety and tolerability of two dosing regimens with LTX-109 administered topically
to the anterior nares in subjects with persistent carriage of Staphylococcus aureus (S.
aureus).